BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Biase S, Pellitteri G, Gigli GL, Valente M. Evaluating pitolisant as a narcolepsy treatment option. Expert Opin Pharmacother 2021;22:155-62. [PMID: 32941089 DOI: 10.1080/14656566.2020.1817387] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Abad VC. Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives. Nat Sci Sleep 2021;13:75-91. [PMID: 33531850 DOI: 10.2147/NSS.S245020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 Pellitteri G, Dolso P, Valente M, Gigli GL. Orgasmolepsy in Narcolepsy Type 1 Responsive to Pitolisant: A Case Report. Nat Sci Sleep 2020;12:1237-40. [PMID: 33408544 DOI: 10.2147/NSS.S286358] [Reference Citation Analysis]
3 Meskill GJ, Davis CW, Zarycranski D, Doliba M, Schwartz JC, Dayno JM. Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials. CNS Drugs 2021. [PMID: 34935103 DOI: 10.1007/s40263-021-00886-x] [Reference Citation Analysis]
4 Midzyanovskaya IS, Birioukova LM, Storvik M, Luijtelaar GV, Tuomisto LM. The prefrontal cortex shows widespread decrease in H3 histamine receptor binding densities in rats with genetic generalized epilepsies. Epilepsy Research 2022. [DOI: 10.1016/j.eplepsyres.2022.106921] [Reference Citation Analysis]